Effects of low doses of N-nitrosomorpholine on the development of early stages of hepatocarcinogenesis. 1995

H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
Institute of Toxicology, Bayer AG, Wuppertal, Germany.

Male Sprague-Dawley rats received the hepatocarcinogen N-nitrosomorpholine (NNM) in the drinking water at low dose levels ranging from 6 mg/l to 60 mg/l for 6 and 12 weeks, respectively. Foci of altered hepatocytes (FAH) were demonstrated histochemically using changes in the activities of glucose-6-phosphate dehydrogenase and glycogen phosphorylase, and in the glycogen content as markers. Proliferating cells were detected by the immunohistochemical reaction for proliferating cell nuclear antigen (PCNA). The number and size of foci of altered hepatocytes increased in a time and dose-related manner. The dose-effect curves were non-linear with a slight positive slope at the low doses and a markedly increased slope at higher doses. The number of PCNA positive hepatocytes showed a dose-dependent increase. In addition to the granular distribution of PCNA in the nuclei, hepatocyte nuclei with homogeneously distributed PCNA occurred in animals exposed to 60 mg/l NNM. It is proposed that these cells are related to the occurrence of hepatocytes with higher ploidy induced by NNM and may be regarded as cells in the G2 phase of the cell cycle. The non-linear shape of the dose-response-curve of the FAH suggests that some mechanisms contribute to carcinogenesis over the whole dose range, whereas other mechanisms enhance carcinogenesis only at higher doses. The relevance of the non-linear dose-effect curve for the risk assessment of carcinogens is discussed.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008112 Liver Glycogen Glycogen stored in the liver. (Dorland, 28th ed) Hepatic Glycogen,Glycogen, Hepatic,Glycogen, Liver
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D008297 Male Males
D009602 Nitrosamines A class of compounds that contain a -NH2 and a -NO radical. Many members of this group have carcinogenic and mutagenic properties. Nitrosamine
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
January 2011, Hepato-gastroenterology,
H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
February 1988, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
November 1991, The American journal of pathology,
H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
June 1997, International journal of cancer,
H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
December 1997, Cancer letters,
H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
August 2002, Experimental and molecular pathology,
H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
December 1996, Cancer letters,
H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
July 2019, Journal of toxicologic pathology,
H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
November 1990, British journal of cancer,
H Enzmann, and H Zerban, and A Kopp-Schneider, and E Löser, and P Bannach
July 1993, British journal of cancer,
Copied contents to your clipboard!